News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
137,226 Results
Type
Article (9412)
Company Profile (63)
Press Release (127751)
Multimedia
Podcasts (21)
Webinars (3)
Section
Business (42662)
Career Advice (161)
Deals (6620)
Drug Delivery (22)
Drug Development (25452)
Employer Resources (22)
FDA (3435)
Job Trends (4027)
News (76133)
Policy (5436)
Tag
Academia (380)
Accelerated approval (2)
Adcomms (10)
Allergies (9)
Alliances (12198)
ALS (11)
Alzheimer's disease (154)
Antibody-drug conjugate (ADC) (104)
Approvals (3476)
Artificial intelligence (85)
Autoimmune disease (3)
Automation (3)
Bankruptcy (59)
Best Places to Work (3555)
BIOSECURE Act (3)
Biosimilars (45)
Biotechnology (53)
Bladder cancer (62)
Brain cancer (22)
Breast cancer (207)
Cancer (1641)
Cardiovascular disease (31)
Career advice (131)
Career pathing (5)
CAR-T (78)
Cell therapy (172)
Cervical cancer (12)
Clinical research (21283)
Collaboration (348)
Compensation (108)
Complete response letters (2)
COVID-19 (394)
CRISPR (11)
C-suite (105)
Cystic fibrosis (1)
Data (775)
Decentralized trials (1)
Depression (6)
Diabetes (27)
Diagnostics (1352)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (49)
Drug pricing (29)
Drug shortages (1)
Duchenne muscular dystrophy (9)
Earnings (14136)
Editorial (12)
Employer branding (8)
Employer resources (22)
Events (24212)
Executive appointments (275)
FDA (3764)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (172)
Gene editing (20)
Generative AI (9)
Gene therapy (72)
GLP-1 (134)
Government (615)
Guidances (17)
Healthcare (4266)
Huntington's disease (5)
IgA nephropathy (13)
Immunology and inflammation (39)
Indications (14)
Infectious disease (414)
Inflammatory bowel disease (28)
Inflation Reduction Act (2)
Influenza (5)
Intellectual property (25)
Interviews (26)
IPO (3131)
IRA (18)
Job creations (694)
Job search strategy (123)
Kidney cancer (11)
Labor market (5)
Layoffs (164)
Leadership (3)
Legal (801)
Liver cancer (42)
Lung cancer (271)
Lymphoma (83)
Machine learning (2)
Management (5)
Manufacturing (56)
MASH (6)
Medical device (902)
Medtech (902)
Mergers & acquisitions (3626)
Metabolic disorders (77)
Multiple sclerosis (12)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (2)
Neuroscience (239)
NextGen: Class of 2025 (1094)
Non-profit (535)
Now hiring (9)
Obesity (44)
Opinion (59)
Ovarian cancer (58)
Pain (7)
Pancreatic cancer (53)
Parkinson's disease (22)
Partnered (2)
Patents (49)
Patient recruitment (32)
Peanut (6)
People (14943)
Pharmaceutical (14)
Pharmacy benefit managers (1)
Phase I (7881)
Phase II (8914)
Phase III (7014)
Pipeline (419)
Policy (37)
Postmarket research (585)
Preclinical (2490)
Press Release (2)
Prostate cancer (83)
Psychedelics (2)
Radiopharmaceuticals (168)
Rare diseases (69)
Real estate (875)
Recruiting (8)
Regulatory (4579)
Reports (8)
Research institute (709)
Resumes & cover letters (30)
RSV (8)
Schizophrenia (16)
Series A (40)
Series B (13)
Service/supplier (1)
Sickle cell disease (21)
Special edition (4)
Spinal muscular atrophy (52)
Sponsored (5)
Startups (929)
State (1)
Stomach cancer (11)
Supply chain (9)
Tariffs (13)
The Weekly (21)
Vaccines (129)
Venture capitalists (16)
Weight loss (23)
Women's health (2)
Date
Today (45)
Last 7 days (282)
Last 30 days (787)
Last 365 days (9352)
2025 (3031)
2024 (9970)
2023 (11127)
2022 (14411)
2021 (14275)
2020 (11905)
2019 (9331)
2018 (6925)
2017 (7836)
2016 (6898)
2015 (7622)
2014 (5072)
2013 (3568)
2012 (3843)
2011 (3807)
2010 (3525)
Location
Africa (119)
Alabama (19)
Alaska (1)
Arizona (18)
Arkansas (2)
Asia (11438)
Australia (1554)
California (1718)
Canada (451)
China (282)
Colorado (52)
Connecticut (76)
Delaware (107)
Europe (22679)
Florida (217)
Georgia (8)
Idaho (6)
Illinois (163)
India (8)
Indiana (57)
Iowa (3)
Japan (73)
Kansas (9)
Kentucky (9)
Maine (3)
Maryland (215)
Massachusetts (1485)
Michigan (18)
Minnesota (66)
Missouri (6)
Montana (5)
Nebraska (3)
Nevada (8)
New Hampshire (8)
New Jersey (472)
New Mexico (3)
New York (417)
North Carolina (187)
Northern California (837)
Ohio (48)
Oklahoma (1)
Oregon (5)
Pennsylvania (270)
Puerto Rico (1)
Rhode Island (4)
South America (153)
South Carolina (2)
Southern California (655)
Tennessee (16)
Texas (282)
United States (6048)
Utah (42)
Virginia (17)
Washington D.C. (8)
Washington State (167)
Wisconsin (13)
137,226 Results for "novartis oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 21st year at ASCO 2024
Novartis Canada is pleased to announce the winners of the 2024 Novartis Oncology Young Canadian Investigator Awards, an annual national competition dedicated to advancing oncology through the promotion of research by supporting Canadian oncology researchers.
June 11, 2024
·
4 min read
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Deals
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.
May 2, 2024
·
3 min read
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
1 of 13,723
Next
